|
|
||||||||
Hypertension and Vascular Disease Center and Department of General Surgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina
Submitted 24 January 2005 ; accepted in final form 12 April 2005
When increased in vascular tissues, angiotensin-converting enzyme 2 (ACE2), a carboxypeptidase that hydrolyzes angiotensin II to angiotensin-(17), may augment the growth inhibitory and vasodilatory effects of the heptapeptide. We investigated the regulation of ACE2 and angiotensin-(17) expression in aortas and carotid arteries of 12-wk-old male spontaneously hypertensive rats (SHR) by determining the effect of sustained angiotensin type 1 (AT1) receptor blockade with olmesartan (10 mg·kg1·day1, n = 13) compared with those that received atenolol (30 mg·kg1·day1, n = 13), hydralazine (10 mg·kg1·day1, n = 13), or vehicle (n = 21). Systolic blood pressures were
30% lower (P < 0.05) in rats treated for 2 wk with olmesartan compared with vehicle-treated rats. Both atenolol and hydralazine produced similar decreases in systolic blood pressure. ACE2 mRNA in the thoracic aorta of olmesartan-treated rats (n = 8) was fivefold greater (P < 0.05) than that in vehicle-treated rats (n = 16), whereas atenolol (n = 8) or hydralazine (n = 8) had no effect. Immunostaining intensities in rats treated with olmesartan (n = 5) were also associated with increased (P < 0.05) ACE2 and angiotensin-(17) in thoracic aorta media compared with vehicle-treated rats. In contrast, immunostaining intensities for both ACE2 and angiotensin-(17) were not different from vehicle (n = 5) in carotid arteries of SHR medicated with either atenolol (n = 5) or hydralazine (n = 5). A comparison of vessel wall dimensions showed that olmesartan selectively reduced the thoracic aorta media-to-lumen ratio (P < 0.05) and media thickness (P < 0.05) without an effect on carotid artery morphometry. Compared with vehicle-treated SHR, vascular hypertrophy determined from media and lumen measurements was not changed in SHR given either atenolol or hydralazine. These data represent the first report of ACE2 and angiotensin-(17) expression in the aorta and carotid arteries of SHR. Increased ACE2 and angiotensin-(17) in association with altered dimensions of the thoracic aorta but not carotid arteries in response to olmesartan treatment provides evidence that this pathway is regulated by AT1 receptors and may be important in mediating the pressure-independent vascular remodeling effects of angiotensin peptides.
angiotensin-converting enzyme 2; angiotensin type 1 receptor; vascular remodeling
This article has been cited by other articles:
![]() |
P. M. Cummins A new addition to the renin-angiotensin peptide family: proAngiotensin-12 (PA12) Cardiovasc Res, April 1, 2009; 82(1): 7 - 8. [Full Text] [PDF] |
||||
![]() |
M. J. Soler, M. Ye, J. Wysocki, J. William, J. Lloveras, and D. Batlle Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan Am J Physiol Renal Physiol, February 1, 2009; 296(2): F398 - F405. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. E. Gallagher, C. M. Ferrario, and E. A. Tallant MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides Am J Physiol Cell Physiol, November 1, 2008; 295(5): C1169 - C1174. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. I. Diz Future Directions in Cardiovascular Pharmacology: Examples from the Renin-Angiotensin System Mol. Interv., October 1, 2008; 8(5): 222 - 225. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gupte, C. M. Boustany-Kari, K. Bharadwaj, S. Police, S. Thatcher, M. C. Gong, V. L. English, and L. A. Cassis ACE2 is expressed in mouse adipocytes and regulated by a high-fat diet Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2008; 295(3): R781 - R788. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Epelman, W.H. W. Tang, S. Y. Chen, F. Van Lente, G. S. Francis, and S. Sen Detection of Soluble Angiotensin-Converting Enzyme 2 in Heart Failure: Insights Into the Endogenous Counter-Regulatory Pathway of the Renin-Angiotensin-Aldosterone System J. Am. Coll. Cardiol., August 26, 2008; 52(9): 750 - 754. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Schindler ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist`s perspective after publication of the results of ONTARGET Therapeutic Advances in Cardiovascular Disease, August 1, 2008; 2(4): 233 - 248. [Abstract] [PDF] |
||||
![]() |
I. Hamming, H. van Goor, A. J. Turner, C. A. Rushworth, A. A. Michaud, P. Corvol, and G. Navis Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats Exp Physiol, May 1, 2008; 93(5): 631 - 638. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Guy, D. W. Lambert, A. J. Turner, and K. E. Porter Functional angiotensin-converting enzyme 2 is expressed in human cardiac myofibroblasts Exp Physiol, May 1, 2008; 93(5): 579 - 588. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Lin, Y. Chen, W. Zhang, A. F. Chen, S. Lin, and M. Morris RNA interference shows interactions between mouse brainstem angiotensin AT1 receptors and angiotensin-converting enzyme 2 Exp Physiol, May 1, 2008; 93(5): 676 - 684. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Koka, X. R. Huang, A. C.K. Chung, W. Wang, L. D. Truong, and H. Y. Lan Angiotensin II Up-Regulates Angiotensin I-Converting Enzyme (ACE), but Down-Regulates ACE2 via the AT1-ERK/p38 MAP Kinase Pathway Am. J. Pathol., May 1, 2008; 172(5): 1174 - 1183. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Feng, X. Yue, H. Xia, S. M. Bindom, P. J. Hickman, C. M. Filipeanu, G. Wu, and E. Lazartigues Angiotensin-Converting Enzyme 2 Overexpression in the Subfornical Organ Prevents the Angiotensin II-Mediated Pressor and Drinking Responses and Is Associated With Angiotensin II Type 1 Receptor Downregulation Circ. Res., March 28, 2008; 102(6): 729 - 736. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Heeneman, J. C. Sluimer, and M. J.A.P. Daemen Angiotensin-Converting Enzyme and Vascular Remodeling Circ. Res., August 31, 2007; 101(5): 441 - 454. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. C De Mello, C. M Ferrario, and J. A Jessup Beneficial versus harmful effects of Angiotensin (1-7) on impulse propagation and cardiac arrhythmias in the failing heart Journal of Renin-Angiotensin-Aldosterone System, June 1, 2007; 8(2): 74 - 80. [Abstract] [PDF] |
||||
![]() |
S. Keidar, M. Kaplan, and A. Gamliel-Lazarovich ACE2 of the heart: From angiotensin I to angiotensin (1-7) Cardiovasc Res, February 1, 2007; 73(3): 463 - 469. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. F. Benter, M. H. M. Yousif, C. Cojocel, M. Al-Maghrebi, and D. I. Diz Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H666 - H672. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Ferrario Angiotensin-Converting Enzyme 2 and Angiotensin-(1-7): An Evolving Story in Cardiovascular Regulation Hypertension, March 1, 2006; 47(3): 515 - 521. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. F. Benter, M. H. M. Yousif, J. T. Anim, C. Cojocel, and D. I. Diz Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H684 - H691. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Ferrario, A. J. Trask, and J. A. Jessup Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2281 - H2290. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. V. Dantas and K. Sandberg Regulation of ACE2 and ANG-(1-7) in the aorta: new insights into the renin-angiotensin system in the control of vascular function Am J Physiol Heart Circ Physiol, September 1, 2005; 289(3): H980 - H981. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |